Parkinson's UK
CompanyUnited KingdomFounded 1969
Parkinson's UK develops one asset, in phase 1 (MTX325 in early stage Parkinson's disease). Mostly small molecule acting on Mitochondrial biogenesis (PGC-1α), autophagy and proteostasis; based in the United Kingdom, founded in 1969.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1Inhibits USP30 to promote mitophagy.
Phase 1, Small molecule, Mitochondrial biogenesis (PGC-1α), Autophagy, early stage Parkinson's disease, mild to moderate Parkinson's disease, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials2
- Signals1
- Similar companies6